Surgery for traumatic optic neuropathy

Yu, Wai Man P; Griffiths, PG

doi:10.1002/14651858.cd005024

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ITON treatments were often focused to decrease the effects of the injurious accident rather than treating the cause [39, 40]. Traditional treatment by high-dose corticosteroids harbors a risk of toxicity to the injured optic nerve and loss of life in patients with accompanying brain injury of up to 21%.…”

Section: Discussionmentioning

confidence: 99%

“…However, early intervention was accused by confounding the results with spontaneous improvement [63]. Some researchers opted to use surgery later after failure of observation and medical treatment [32, 39]. In the presence of safer and more potent alternatives like intravitreal EPO injection, risky surgeries should be avoided to prevent serious complications like ophthalmic or carotid artery injury, CSF leak, and infection [54].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Visual-Evoked-Response-Supported Outcome of Intravitreal Erythropoietin in Management of Indirect Traumatic Optic Neuropathy

Rashad

latif

Mostafa

et al. 2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose Investigating the efficacy of intravitreal injection of erythropoietin (EPO) in managing indirect traumatic optic neuropathy (ITON) of different durations. Methods A case series that included two groups of ITON patients: recent ITON group (<3 months trauma duration; 7 eyes) and old duration ITON group (3–36 months; 7 eyes). Diagnostic computerized tomography (CT) and baseline flash visual evoked response (VER) were performed at the presentation time. At the initial visit and each follow-up, all patients had undergone assessment of best-corrected visual acuity (BCVA), pupil reaction, and anterior and posterior segments. VER was repeated 1 and 3 months after injection. All patients received an intravitreal injection of 2000 IU EPO in 0.2 ml of commercially available sterile EPREX 4000 solution, Jansen Cilag, Zug, Switzerland. Five patients had received a second injection 3 months later. Results Significant improvement was found in BCVA, VER amplitude, and latency (P < 0.0001, 0.0154, and 0.0291, respectively). Initial values of BCVA, VER amplitude, and latency correlated significantly to the final values. Differences between recent and old trauma groups were insignificant in the three parameters. In patients who received second injection, further clinical but statistically insignificant improvement was noted in BCVA in 60% of patients, VER amplitude in 50% of patients, and in VER latency in 100% of patients. No complications were recorded. Conclusion Intravitreal injection of EPO may be effective and safe in treatment of recent and old indirect traumatic optic neuropathy.

show abstract

Section: Discussionmentioning

confidence: 99%